• helpdesk@Lucintel.com
  • |
  • +1 972 636 5056
  • |
  • Login
  • |
  • Register
  • |
  • Search
  • |

The Impact of COVID-19 is included in Metabolomics Market. Buy it today to get an advantage.

Request the impact of COVID-19 on your product or industry

The future of the global metabolomics market looks promising with opportunities in various appliations, such as biomarker discovery, drug discovery, toxicology testing, nutrigenomics, functional genomics, and personalized medicine. The global metabolomics market is expected to grow with a CAGR of 13%-15% from 2020 to 2025. The major drivers for this market are increasing research and development activities in pharmaceutical and biotechnology and increasing prevalence of chronic diseases.
Emerging trends, which have a direct impact on the dynamics of the industry, include  growing adoption of HPLC and UPLC technique for its most versatile separation method.  
A total of XX figures / charts and XX tables are provided in this more than 150-pages report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global metabolomics market report, please download the report brochure.
In this market, metabolomics instruments is the largest product and service of metabolomics, whereas biomarker discovery is the largest application. Growth in various segments of the metabolomics market are given below:

The study includes trends and forecast for the global metabolomics market by product and service, application, indication, and region as follows:
By Product and Service [Value ($ Million) shipment analysis for 2014 – 2025]:
  • Metabolomics Instruments
  • Separation Tools
  • Detection Tools 
  • Metabolomics Bioinformatics Tools and Services
By Application [Value ($ Million) shipment analysis for 2014 – 2025]:
  • Biomarker Discovery
  • Drug Discovery
  • Toxicology Testing
  • Nutrigenomics
  • Functional Genomics
  • Personalized Medicine
  • Other Applications
By Indication [Value ($ Million) shipment analysis for 2014 – 2025]: 
  • Cancer
  • Cardiovascular Disorders
  • Neurological Disorders
  • Inborn Errors of Metabolism
  • Other Indications
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
  • North America
  • United States
  • Canada 
  • Mexico
  • Europe
  • United Kingdom
  • German
  • France
  • Asia Pacific
  • China
  • India
  • Japan
  • The Rest of the World 
  • Brazil
Some of the metabolomics companies profiled in this report include Agilent Technologies, Bio- Rad Laboratories, Bruker Corporation, Danaher, Thermo Fisher Scientific, Waters Corporation, Shimadzu Corporation, LECO Corporation, Biocrates Life Sciences, and Metabolon.